Physician profile
Sean M Ormond
NPI 1699118943
$11,327.54
in general payments reported to CMS, 2019-2025
36 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $1,033 · 2021: $2,839 · 2022: $1,780 · 2023: $1,183 · 2024: $2,046 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,376.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,699.95 | 2019-2025 | Proclaim, Eterna, Penta |
| Boston Scientific Corporation | $1,915.73 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Medtronic, INC. | $542.97 | 2023-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Inceptiv |
| Nalu Medical, INC. | $310.63 | 2021-2024 | Nalu Neurostimulation System |
| Nuvasive, INC. | $203.58 | 2022-2023 | Alif, Tlif |
| Nevro Corp. | $198.69 | 2021-2023 | Senza |
| Abbvie INC. | $124.28 | 2022-2024 | |
| Vertos Medical, INC. | $110.71 | 2021-2024 | Mild Device Kit |
| Spinefrontier, INC. | $105.73 | 2024 | Sijfuse |
| Ibsa Pharma INC. | $101.67 | 2023-2025 | Tirosint, Licart, Tirosint |
| Collegium Pharmaceutical, INC. | $83.78 | 2021-2023 | Xtampza |
| Si-Bone, INC. | $81.78 | 2024 | |
| Bioventus LLC | $78.60 | 2022-2025 | Gelsyn-3 |
| Pfizer INC. | $71.98 | 2023-2024 | |
| Electronic Waveform Lab, INC. | $71.22 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $63.37 | 2023-2024 | Roxybond |
| Biotronik Nro, INC. | $52.58 | 2024-2025 | Prospera |
| Spr Therapeutics, INC | $52.56 | 2021-2025 | Sprint Pns System |
| Biodelivery Sciences International, INC. | $49.66 | 2019-2020 | |
| Fidia Pharma USA INC. | $46.20 | 2024 | Hymovis |
| Saluda Medical Americas, INC. | $41.56 | 2023-2025 | Evoke, Evoke Scs |
| Almatica Pharma LLC | $37.31 | 2022-2023 | Gralise |
| Biohaven Pharmaceuticals, INC. | $35.95 | 2021 | |
| Shionogi INC | $35.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.30 | 2022-2023 | Seglentis |
| Daiichi Sankyo INC. | $23.04 | 2019 | |
| Tonix Medicines, INC. | $21.75 | 2025 | Tonmya |
| Ferring Pharmaceuticals INC. | $20.12 | 2020 | |
| Foundation Fusion Solutions, LLC | $20.07 | 2025 | |
| Globus Medical, INC. | $17.73 | 2025 | Senza |
| Medtronic USA, INC. | $17.03 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.90 | 2022 | |
| Mml US, INC. | $15.66 | 2025 | Reactiv8 |
| Orthogenrx INC. | $15.38 | 2021 | |
| Amgen INC. | $11.73 | 2022 | |
| Stratus Medical, LLC | $6.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Ormond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.